Beam Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Good morning, everyone. My name is Gena Wang. I'm SMid-Cap Biotech Analyst at Barclays. Welcome to Barclays Global Healthcare Conference. It is my great pleasure to introduce our next presenting company, Beam Therapeutics. With us, we have Giuseppe Pino Ciaramella, Chief Scientific Officer and President.
Pino, do you want to give a brief overview before we dive into specific questions?
Yes, of course. And thank you very much for the opportunity to come and share some of our updates. Yes, so Beam Therapeutics is a next-generation gene-editing company that uses primarily this technology known as base editing. It is still a Cas9-based technology. But we use Cas9 as the landing pad and the targeting domain. But we have changed in a very important way so it no longer makes the double-stranded break, which we believe leads to some unwanted outcomes in editing.
Instead, fuse to the protease, is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
